Registrations Open Now!

Ametris Digital Data Summit 2027
February 8-10 | ATLANTA, GA

Advancing Digital Measures Towards Scalable Clinical Impact
Join us for the Ametris Digital Data Summit 2027! Now in its fifth year, ADDS is heading to Atlanta once again to facilitate easier access and expanded space and support our growing community. ADDS is a one-of-a-kind scientific conference advancing the adoption of wearable digital health technologies (DHTs) in clinical research by bringing together a multidisciplinary group of digital health leaders for expert-led presentations and collaborative discussions.
Featured Speakers
-

Dana Wolff-Huges, PhD
Program Officer
National Cancer Institute
-

Raul Torres, PhD
Associate Director, Data Science
Takeda
-

Daniel Lachant
Associate Professor of Medicine
University of Rochester Medical Center
-

Jie Ren, PhD
Director, Data Science
Merck
-

Dr. Paul Hibbing, PhD
Assistant Professor
University of Illinois Chicago Department of Kinesiology and Nutrition
-

Dana Wolff-Huges, PhD
Program Officer
National Cancer Institute
-

Raul Torres, PhD
Associate Director, Data Science
Takeda
-

Daniel Lachant
Associate Professor of Medicine
University of Rochester Medical Center
-

Jie Ren, PhD
Director, Data Science
Merck
-

Dr. Paul Hibbing, PhD
Assistant Professor
University of Illinois Chicago Department of Kinesiology and Nutrition
Check back regularly for new speakers!
Why Attend ADDS 2027
ADDS is your chance to learn from, network with, and develop collaborations with colleagues from a variety of disciplines, including clinicians, data scientists, clinical trialists, digital health technology specialists, and public health researchers.
Client Case
Studies
Networking
Forums
Scientific Poster
Session
Panel
Discussions
Pre-Conference Workshop
Parkinson's Disease
Monday, February 8th
The MDS-UPDRS Part III remains the standard motor endpoint in early Parkinson's disease trials, yet a machine-learned measure from wrist accelerometry has been shown to detect disease progression in prodromal Parkinson’s Disease (PD) more sensitively than this scale — with wearable-sensors elsewhere reaching statistically significant, progression-consistent change within roughly ten months and larger two-year effect sizes than conventional clinical rating in early-stage disease.
This session challenges sponsors to reconsider whether episodic clinical scales alone are sensitive enough for early-population trials, then tailors the evidence to the room: biostatisticians will see the power and sample-size case for continuous digital endpoints; operations leads will see the wear-compliance and data-pipeline requirements; regulatory leads will see how composite construction (reference-based vs. reference-free) affects qualification strength.
The session closes with a clear position: in early and phase I/II PD trials, sensor-based composite measures are a validated complement to clinical rating, not an exploratory add-on — and omitting one risks underpowering detection of true treatment effects.
Seats are limited! Please check the box on the ticket form to reserve your seat.
Scientific Poster Session
If you have original, unpublished research that involves the use of digital health technologies (DHTs), including wearables, sensors, and/or eCOA, we invite you to submit your abstract for consideration for ADDS 2027 Scientific Poster Session!
What Did Attendees Say About ADDS?
It's nice to have a conference that has a very specific focus, because we can dive much deeper into that and really get into the meat of the data. You can get into a much deeper understanding of the particular topic as well as some of the advancements in the field.
Ariel Dowling, PhD
Head of Sensing and Measurement | Takeda
It's a perfect thing when you can come to a conference, and you can meet people and immediately realize that you have things in common and can help each other; to meet other people who are really in different fields, but experiencing some of the same issues and develop potential collaborations across the board.
Johathan Soslow
Pediatric Cardiologist | Vanderbuilt University
An event like this brings talent that you normally are not exposed to, and as you see these presentations, you're shocked as to how much innovation is out there.
Peter Fernandes
CEO | Bellerophon Therapeutics
I think a lot of us do research in the technology and how we can apply it to our specific research interests or populations, but learning how to cross those boundaries between clinical populations is important.
Jennifer Schrack
Professor of Epidemiology and Medicine | Johns Hopkins Bloomberg School of Public Health


